基于孟加拉国既往疫情评估尼帕疫苗效力试验可行性
研究基于孟加拉国既往尼帕病毒病例进行模拟,假设疫苗效力90%等目标特征,比较环状接种、大规模接种和观察性病例对照三种设计。若不改变流行病学,III期疫苗试验难以在合理时间内完成。
核心结论
- 在当前尼帕病毒流行病学条件下,环状接种或大规模接种III期疫苗试验难以在合理时间窗内完成。
- 替代选择包括等待流行病学变化、采用观察性研究或动物规则下对照研究等方式支持许可。
研究设计与样本
- 基于孟加拉国既往观察到的尼帕病毒病例进行模拟研究。
- 假设疫苗效力为90%及其他尼帕疫苗目标特征。
- 比较三种接种研究设计:集群随机环状接种、集群随机大规模接种和观察性病例对照研究。
主要发现
- 假设10天爬升期和平均4天住院延迟,集群随机环状接种试验需516年和超过163,000剂疫苗。
关键数值与推荐
- 模拟假设疫苗效力为90%。
- 环状接种模拟假设10天爬升期和平均4天住院延迟。
临床怎么用
- 提示在尼帕病毒低散发背景下,传统III期疫苗效力试验可行性低。
- 疫苗效力评估可考虑观察性设计或动物规则等替代路径。
局限性
- 研究基于孟加拉国既往病例的模拟,假设疫苗效力90%等目标特征。
- 结果依赖于当前尼帕病毒流行病学条件,未考虑疫情变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nipah virus (NiV) is an emerging, bat-borne pathogen that can be transmitted from person-to-person. Vaccines are currently being developed for NiV, and studies have been funded to evaluate their safety and immunogenicity. An important unanswered question is whether it will be possible to evaluate the efficacy of vaccine candidates in phase III clinical trials in a context where spillovers from the zoonotic reservoir are infrequent and associated with small outbreaks. The objective of this study was to investigate the feasibility of conducting a phase III vaccine trial in Bangladesh, the only country regularly reporting NiV cases. METHODS: We used simulations based on previously observed NiV cases from Bangladesh, an assumed vaccine efficacy of 90% and other NiV vaccine target characteristics, to compare three vaccination study designs: (i) cluster randomized ring vaccination, (ii) cluster randomized mass vaccination, and (iii) an observational case-control study design. RESULTS: The simulations showed that, assuming a ramp-up period of 10 days and a mean hospitalization delay of 4 days,a cluster-randomized ring vaccination trial would require 516 years and over 163,000 vaccine doses to run a ring vaccination trial under current epidemic conditions. A cluster-randomized mass vaccination trial in the two most affected districts would take 43 years and 1.83 million vaccine doses. An observational case-control design in these two districts would require seven years and 2.5 million vaccine doses. DISCUSSION: Without a change in the epidemiology of NiV, ring vaccination or mass vaccination trials are unlikely to be completed within a reasonable time window. In this light, the remaining options are: (i) not conducting a phase III trial until the epidemiology of NiV changes, (ii) identifying alternative ways to licensure such as observational studies or controlled studies in animals such as in the US Food and Drug Administration's (FDA) Animal Rule.
引用
- Nikolay B, Ribeiro Dos Santos G, Lipsitch M, et al. Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh. Vaccine. 2021. PMID: 34426025. doi:10.1016/j.vaccine.2021.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。